Thursday, April, 18, 2019 08:44:56

Category: Biotechnology

Catalent Inc to acquire Paragon Bioservices in a $1.2 billion deal

The acquisition would be helping Catalent in expanding its capabilities of developing costly & specialized gene therapy treatments. The company would be carrying out the acquisition through an all-cash deal, scheduled to be announced soon. Catalent, Inc., (Catalent), a New Jersey-based technology & pharmaceutical firm, …

Novacyt, Immunexpress expand contract for developing diagnostic assays

The partnership expansion would further support the development of rapid diagnostic assays needed for detecting sepsis Novacyt, a global clinical diagnostics specialist, has recently announced that Primerdesign Ltd, its molecular testing division, has expanded its assay development contract with Immunexpress, Inc., a molecular diagnostic company …

Cellgen, GTC unite to develop companion tests for cancer therapies

The two firms will focus on accelerating global development of companion tests for several oncology therapies. Renowned precision diagnostics firm, Cellgen Diagnostics has recently announced a strategic collaboration with Genomic Testing Cooperative (GTC) to help accelerate global development of companion tests for various oncology therapeutics. …

Sangamo & Pfizer unveil data from gene therapy for severe hemophilia A

More than eight individuals treated with the SB-525 gene therapy demonstrated increases in FVIII activity that was dose-dependent. The FVIII levels reached normal in two patients that were treated with a 3e13 vg/kg dose. Sangamo Therapeutics, Inc., (Sangamo), a California-based biotechnology company, and New York-based …

Biohaven’s first patient enrolled in Phase 3 Troriluzole trial

Biohaven recently announced the expanded data from the Phase IIb/III long-term extension study of troriluzole, with its comparison to coordinated natural history cohort Biohaven Pharmaceutical Holding Company Ltd., a U.S.-based clinical-stage biopharmaceutical company, has made it to the front page with the enrollment of its …

TLC and 3SBio partner to commercialize two NanoX products in China

A clinical-stage specialty pharmaceutical company Taiwan Liposome Company Ltd. and 3SBio Inc, China’s leading biopharmaceutical company have reportedly  entered into an exclusive partnership intended to commercialize two liposomal products in China, using TLC’s proprietary NanoX technology platform. As per the alliance, TLC and 3SBio will …